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Abstract
Proteus syndrome (PS) is an extremely rare and complex disease characterized by malformations and overgrowth of
different tissues. Prognosis of affected patients may be complicated by premature death, mostly due to pulmonary
embolism and respiratory failure. To date, immunological data in Proteus syndrome are scarse.
We report on the novel immunologic findings of a 15 years old girl affected with PS. Detailed T and B cell evaluation
revealed maturational alterations for both subsets and functional hyperactivation for the latter. Such findings have not
been reported previously in PS and may be the spy of more complex immune abnormalities in this syndrome.
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Correspondence
The Proteus syndrome (PS) is an extremely rare and com-
plex disease characterized by malformations and over-
growth of various tissues, mainly connective tissue, bone,
skin, and central nervous system, although any tissue may
be involved [1–6]. Clinical manifestations are highly vari-
able and the disproportionate overgrowth of tissue is usu-
ally asymmetrical and involves the arms, legs, hands, feet
and digits. The complications of PS include hyperostosis,
cerebriform connective tissue progressive, skeletal de-
formities, benign and malignant tumors, capillary vascular
malformations and deep venous thrombosis with pulmon-
ary embolism.
The syndrome has an incidence of less than 1 per
1,000.000 live births and is estimated that 120 individuals
with PS are currently alive worldwide [3–5]. Newborns
with Proteus syndrome have few or no signs of the condi-
tion, and overgrowth becomes apparent between 6 and
18 months of life, getting more severe with age [6]. Lesions
appear to be distributed in a mosaic manner and have a
progressive evolution. Recently, a mosaic activating muta-
tion in AKT1 was reported to be associated with PS [7].
Published immunological data for PS are scarse: in
fact, only one patient has been reported to date with
mild hypogammaglobulinemia and lymphopenia leading
to reduction of total T and B cell numbers [8].
Case report
We report the case of a 15 years old girl with Proteus syn-
drome and describe novel immunological findings in PS.
The index patient, born to non consanguineous parents,
was born via caesarian section at 36 weeks of gestation,
with normal weight and length (3500 g and 50 cm, respect-
ively). Diagnosis of PS was made at the age of 2 years, with
progressive overgrowth over time. The index patient pre-
sented multiple lesions affecting the central nervous and
circulatory system, lung, skeleton, limbs and abdominal or-
gans. The phenotypic examination showed dolichocephaly,
hyperostosis of the skull in the right fronto-parietal area, fa-
cial dysmorphic features with facial asymmetry and ptosis
of right eye, depressed nasal bridge, wide and anteverted
nares, oligodontia and multiple caries, long neck. The pa-
tient presented thin skin, adipose dysregulation with poorly
represented subcutaneous adipose and a disproportionate,
asymmetric overgrowth of the limbs. The index patient pre-
sented important overgrowth of the feet (Fig. 1a, left panel)
with greater growth of the calcaneus and cuboid, especially
of the left foot (Fig. 1a, right panel). The patient also pre-
sented severe kyphoscoliosis (Fig. 1b) and length discrep-
ancy and macrodactyly in the III and IV fingers of right
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hand (Fig. 1c), emphysema, pulmonary fibrosis, syringo-
myelic cavity of about 2 cm in the section C3-D4, and
ovarian cystadenomas. During follow-up, the patient de-
veloped portal thrombosis at 12 years of age with portal
splenic and mesenteric hypertension and liver atrophy and
suffered from a transient ischemic attack (TIA) at the age
of 13. Brain magnetic resonance imaging (MRI) showed
cortical dysplasia with marked thickening of the skull in
the right fronto-temporal (Fig. 1d, e and f) which in-
creased in volume over 4 years reaching 44 mm with
significant compression on the midbrain, brain paren-
chyma and cerebral edema, hydrocephalus and proptosis
of the right eye (Fig. 1e). The significant progression
of the lesions determined respiratory failure, coma,
and subsequent death of the patient.
Immunological evaluation of the index patients revealed
several novel findings. Immunoglobulin serum levels were
within normal range, in contrast with previously reported
data [8] in the presence of valid humoral response to
vaccinations (Table 1). Interestingly, both the index
Fig. 1 Clinical and radiologic presentation of the index PS patient. a Overgrowth of the feet (left panel) with radiologic confirmation of bone
overgrowth, especially of the left foot (righ panel). b Severe cyphoscoliosis of the index patient. c Length discrepancy and macrodactyly in the III
and IV fingers of right hand from the index patient. d e and f Coronal flair (d) and axial flair (e) weighted images demonstrated hyperostosis of
the right fronto-parietal cranial vault (black asterisk) with proptosis of the right eye and extensive malformation of cortical development involving
predominantly the right cerebral hemisphere but also part of the left cerebral hemisphere. There is an extensive white matter signal abnormality
of both hemispheres (white arrows); there is also an associated malformation of the brainstem. Coronal T2 weighted images (f) show hyperostosis of
the right fronto-parietal cranial vault (black asterisk), extensive malformation of the right hemisphere with white matter changes in the periventricular
region (white arrows); malformation of cortex in the left perisylvian region (red arrow)
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patient and the single patient reported previously [8]
were lymphopenic (Table 1), with consequently reduced
peripheral total T and B cell numbers (Table 1), without
however a significant history of infections. Thus, a more
detailed evaluation of the peripheral lymphocyte subsets
from the index PS patient was performed and revealed,
within the T cell population, normal thymic output as
defined by normal naive (CD45RA+CCR7+) and recent
thymic emigrants (RTE) (CD45RA+CCR7+CD31+) CD4 T
cell percentages, an increase in the Terminally differenti-
ated CD45RA+CCR7− CD4 T cells and a reduction of the
CD8 T cells (Table 1). The B cell population showed a
reduction in the RBE (Recent Bone Marrow Emigrants:
CD38hiCD21dim/loCD27−) subset and in the IgM memory
subset (IgD+CD27+), while all other subsets appeared
normally distributed in terms of percentages (Table 1). No
Table 1 Immunological evaluation of the index PS patient
Patient code Index patient Normal range for age (index patient) Published patient [8]
Sex Female Male
Age (onset) 2 years n.a.
Age (evaluation) 14 years 10 years
IgG (mg/dl) 1110 (604–1909) 280
IgA (mg/dl) 100 (61–301) 40
IgM (mg/dl) 105 (59–297) 50
Anti-tetanus toxoid antibodies (UI/ml) 0,15
Anti-diphtheria antibodies (UI/ml) 0,12
Total lymphocyte count (/mm3) 736 ↓↓ (1340–3173) 470
T cell counts/ml 437 ↓↓ (954–2332) 100
B cell counts/ml 164 ↓ (173–685) 100
% (absolute cell number/μl) Normal percentage range for age
(range of absolute cell number/μl for age)
(index patient)
T cells (CD3+) 59,3 ↓ (437 ↓↓) 60,5–79,8 (954–2332) n.a.
CD3+CD4+ 43,2 (318 ↓↓) 30,3–48,3 (635–1334) n.a.
Naive (CD45RA+CCR7+) 49,9 (159 ↓) 34,3–74,6 (276–828) n.a.
RTE (CD45RA+CCR7+CD31+) 39,9 (127) 21,1–63,5 (21–699) n.a.
Central memory (CD45RA−CCR7+) 22,6 (72 ↓) 13,0–43,5 (107–420) n.a.
Effector memory (CD45RA−CCR7−) 19,5 (62 ↓) 8,5–28,1 (95–261) n.a.
Terminally differentiated (CD45RA+CCR7−) 7,6 ↑ (24) 0,7–6,6 (6–61) n.a.
CD3+CD8+ 9,1 ↓↓ (40 ↓↓↓) 13,8–37,5 (276–1035) n.a.
Naive (CD45RA+CCR7+) 58,5 (23,4 ↓↓↓) 26,7–72,9 (117–454) n.a.
Central memory (CD45RA−CCR7+) 10,2 (4 ↓) 1,2–11,6 (8–85) n.a.
Effector memory (CD45RA−CCR7−) 15,6 (6 ↓↓) 6,0–53,6 (19–536) n.a.
Terminally differentiated (CD45RA+CCR7−) 15,5 (6 ↓↓) 3,9–72,0 (13–699) n.a.
TCR γ/δ 3,3 (1) 0,5–21,5 n.a.
B cells (CD19+) 22,3 (164 ↓) 5,7–19,7 (173–685) n.a.
RBE (CD38hiCD21dim/loCD27−) 12,1 ↓ (20) 15,0–35,3 (20–179) n.a.
Naive (CD38dim/loCD21hiCD27−) 66,1 (108) 33,8–79,6 (40–398) n.a.
CD19hiCD21lo 6,3 (10) 1,1–10 (5–17) n.a.
Switched memory (IgD−CD27+) 8,8 (14) 2,7–20,6 (7–45) n.a.
IgM memory (IgD+CD27+) 2,5 ↓ (4 ↓↓) 3,5–24,1 (10–49) n.a.
Terminally differentiated (CD38hiCD27hiCD21lo) 0,55 (0,5) 0,16–8,70 (0,4–11) n.a.
Plasmacells (CD38hiCD20−CD138+) 0,21 (0,5) 0,04–3,20 (0,1–5,2) n.a.
NK cells (CD3−CD16+CD56+) 11,0 (81 ↓) 4,6–27,8 (111–539) n.a.
(Comparison with the only published immunological data from a single PS patient is included where data were available)
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alterations were observed in the natural killer (NK) cell
subsets. T and B cell activation was evaluated by in vitro
stimulation with phytohemaggluttinin (PHA) and CpG
respectively and measured by the up-regulation of
surface activation markers. T cell activation upon (PHA)
stimulation as measured by CD69 up-regulation was
similar to that of the healthy control (data not shown). Pa-
tient’s B cells on the other hand showed an increased
up-regulation of CD69 and CD86 upon CpG stimula-
tion when compared to the healthy control (Fig. 2a
and b respectively), suggestive of B cell hyper respon-
siveness in PS.
Our immunological data suggest that PS patients may
present T and B cell alterations in terms of maturation
and activation. This is a novel finding in PS and, together
with the presence of lymphopenia, adds further complex-
ity to this disorder. The in vitro hyper-responsiveness
observed in B cells from the PS patient may be related to
the role of AKT kinases in B cell biology in terms of
apoptosis, survival and maturation, as observed in the
animal model [9]. Unfortunately, and due to the prema-
ture death of the index patient, genetic analysis for the
AKT1 mutation was not performed. Further studies in
more PS patients would be of interest for better under-
standing the immune alterations in this rare and complex
disorder.
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Fig. 2 B cell in vitro activation from the index patient. a B cells from the index patient and a healthy control (HD) were stimulated with CpG and
CD69 up-regulation was evaluated by flow-cytometry after overnight incubation. b B cells from the index patient and a healthy control (HD) were
stimulated with CpG and CD86 up-regulation was evaluated by flow-cytometry after overnight incubation. Red circles depict the activated
cell populations
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